The table below shows CRISPR Therapeutics AG's income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q3 2025
Q2 2025
Q1 2025
Q3 2024
Q2 2024
Revenue
$1.46M
$889.00K
$892.00K
$865.00K
$602.00K
$517.00K
Cost of revenue
-
-
-
-
-
-
Gross profit
-
-
-
-
-
-
R&D
$68.57M
$58.90M
$69.89M
$72.48M
$82.16M
$80.17M
CRSP annual revenue (10-K history)
CRISPR Therapeutics AG reported annual revenue of $3.51M for fiscal year 2025. That is down 90.6% from $37.31M in fiscal 2024. Over the 10 fiscal years shown, annual revenue declined from $5.16M (FY 2016) to $3.51M. Figures come from the company's audited annual reports as filed with the SEC.
